LYB — LyondellBasell Industries N.V.

The market is bullish because Q2 2026 adjusted EPS of $4.30 beat consensus by more than 25%, adjusted EBITDA of $2.13B nearly tripled Q1, and Middle East polyethylene supply disruptions could keep roughly 6 million tons of capacity offline into 2027. Analyst consensus is Buy with a $70.82 target, though a meaningful hold/sell minority means the market is not unanimously convinced the earnings surge is durable.

The trend inflected sharply in Q2 2026. Revenue jumped from $7.20B in Q1 2026 to $9.18B in Q2 2026, up ~20% year over year, while operating income swung from $239M to $1.54B and gross margin expanded from ~9.7% to ~22.2%. Before that, LYB was grinding through a cyclical downturn with repeated impairments in Q4 2024 and Q3 2025. This looks like a genuine cyclical turn from a depressed base, not a steady uptrend yet, and the near-term driver is an external supply shock rather than broad end-market strength.

GAAP TTM valuation is distorted by impairments: P/E is -56.3x and EPS is -$1.08, so PEG of 0.05 is meaningless. On forward numbers, LYB trades at about 6.8x next-FY consensus EPS of $9.26, well below its 5-year average P/E of 11.26x. P/S of 0.65x is near the 5-year average of 0.60x and roughly half the specialty-chemical sector average. Price/book of 1.91x and a 5.28% dividend yield add a value cushion. Excluding impairment noise, the stock is cheap relative to its own history and to normalized earnings power.

At $63.06, the market is treating Q2 2026's surge as temporary and refusing to give the stock a full recovery multiple. If next-FY EPS of $9.26 is even close to correct, LYB is priced for a below-average multiple and can re-rate toward the $70-80s as earnings deliver. If Middle East capacity returns early or industrial demand weakens, EPS could fall back toward $5-6 and fair value would sit closer to the $40-50 range. The asymmetry currently favors the upside, but it is a cyclical bet, not a stable-compounder bet.

As of 2026-08-27, RSI is 50.79, neutral rather than overbought or oversold. Price is -0.27% versus the 20-day SMA, +5.33% versus the 50-day SMA, and +5.34% versus the 200-day SMA. That is a consolidation above rising moving averages after a strong run off the lows, with no technical red flag. Entry timing is reasonable, but patient buyers could wait for a breakout above the recent range or a pullback toward the 50-day SMA before adding.

• Middle East polyethylene supply outages of roughly 20-25% of regional supply are tightening global polymer markets and supporting margins into 2027.
• Sluggish European and broader industrial demand remains the main volume headwind, prompting LYB to prune high-cost European assets.
• Rising recycled-content mandates and single-use plastic regulations favor LYB's circular chemicals investments, including MoReTec.
• A 5.28% dividend yield makes the stock rate-sensitive: high-for-longer rates pressure valuation, while falling rates could trigger multiple expansion.

• Q3 2026 earnings in late October/early November: confirmation that Middle East outages persist and August polyethylene price hikes hold.
• Commercial commissioning of the Wesseling MoReTec chemical recycling facility later in 2026.
• Delivery on the Cash Improvement Plan, targeting $500M incremental cash flow by year-end 2026, plus debt reduction or further capital returns.

• Premature restoration of Middle East supply or a global demand recession would compress polyethylene margins and erase much of the Q2 beat.
• Leverage is real: long-term debt of $11.2B and debt-to-equity of 1.33x reduce cushion if the cycle turns down again.
• Execution risk on European asset divestitures and unproven large-scale chemical recycling economics.

LYB is a cyclical chemicals company coming out of a depressed trough, with a concrete near-term tailwind from Middle East supply disruptions. At $63.06, roughly 6.8x next-FY EPS and a 5.28% yield, the risk/reward is favorable for a patient, volatility-tolerant investor. The main mistake would be treating the Q2 2026 margin spike as a permanent new normal rather than a cyclical upswing.

I applied an 8.1x P/E multiple to next-FY consensus EPS of $9.26. That multiple is roughly 28% below LYB's 5-year average P/E of 11.26x to reflect cyclicality, leverage, and European structural drag, but well above the market's current implied 6.8x forward multiple, resulting in a fair value of approximately $75.00.